These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [The importance of mutational status in prognosis and therapy of GIST]. Comandone A; Boglione A Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775 [TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors. Lim KH; Huang MJ; Chen LT; Wang TE; Liu CL; Chang CS; Liu MC; Hsieh RK; Tzen CY Med Oncol; 2008; 25(2):207-13. PubMed ID: 18488160 [TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors. Wang CM; Huang K; Zhou Y; Du CY; Ye YW; Fu H; Zhou XY; Shi YQ J Cancer Res Clin Oncol; 2010 Jul; 136(7):1065-71. PubMed ID: 20043176 [TBL] [Abstract][Full Text] [Related]
8. Molecular research directions in the management of gastrointestinal stromal tumors. Tarn C; Godwin AK Curr Treat Options Oncol; 2005 Nov; 6(6):473-86. PubMed ID: 16242052 [TBL] [Abstract][Full Text] [Related]
9. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Lasota J; Miettinen M Semin Diagn Pathol; 2006 May; 23(2):91-102. PubMed ID: 17193822 [TBL] [Abstract][Full Text] [Related]
10. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hornick JL; Fletcher CD Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861 [TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. Liegl B; Kepten I; Le C; Zhu M; Demetri GD; Heinrich MC; Fletcher CD; Corless CL; Fletcher JA J Pathol; 2008 Sep; 216(1):64-74. PubMed ID: 18623623 [TBL] [Abstract][Full Text] [Related]
13. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537 [TBL] [Abstract][Full Text] [Related]
14. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Gounder MM; Maki RG Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1(Suppl 1):S25-43. PubMed ID: 21116624 [TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Croom KF; Perry CM Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228 [TBL] [Abstract][Full Text] [Related]
16. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis. Lee JH; Kim Y; Choi JW; Kim YS J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323 [TBL] [Abstract][Full Text] [Related]
17. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. Heinrich MC; Maki RG; Corless CL; Antonescu CR; Harlow A; Griffith D; Town A; McKinley A; Ou WB; Fletcher JA; Fletcher CD; Huang X; Cohen DP; Baum CM; Demetri GD J Clin Oncol; 2008 Nov; 26(33):5352-9. PubMed ID: 18955458 [TBL] [Abstract][Full Text] [Related]
18. Molecular basis and management of gastrointestinal stromal tumors. Bayraktar UD; Bayraktar S; Rocha-Lima CM World J Gastroenterol; 2010 Jun; 16(22):2726-34. PubMed ID: 20533592 [TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors. Nishida T; Doi T; Naito Y Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162 [TBL] [Abstract][Full Text] [Related]
20. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Miranda C; Nucifora M; Molinari F; Conca E; Anania MC; Bordoni A; Saletti P; Mazzucchelli L; Pilotti S; Pierotti MA; Tamborini E; Greco A; Frattini M Clin Cancer Res; 2012 Mar; 18(6):1769-76. PubMed ID: 22282465 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]